Shots:
- The companies collaborated to evaluate the safety, PK & antiviral activity of ATI-2173, vebicorvir & TDF in an ongoing P-IIa ANTT201 trial in 10 treatment naïve or off-treatment HBeAg negative or positive patients with chronic HBV infection. The cohort is expected to start in H1’22
- ATI-2173 has demonstrated a well-tolerated safety profile & uses an ASPIN mechanism in clinical development for combination therapy. ATI-2173 is currently being evaluated in P-II clinical development
- In P-II trials, vebicorvir was administered with NrtI therapy & demonstrated a favorable safety profile & led to greater viral suppression of HBV DNA & HBV pgRNA over NrtI therapy alone
Click here to read the full press release/ article | Ref: PR Newswire | Image: Inf.News
The post Antios Enters into a Clinical Collaboration Agreement with Assembly Biosciences to Evaluate ATI-2173 and Vebicorvir for Chronic Hepatitis B Virus Infection first appeared on PharmaShots.
